Trial: 202003048

A Phase 3, Randomized, Double-Blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle-invasive Bladder Cancer (MIBC)

Phase

III

Principal Investigator

Michalski, Jeff

Disease Site

Urinary Bladder

Learn more about this study at: clinicaltrials.gov